Creating a digital diagnostic that is supplemental and strategic to a company’s therapeutic asset requires due diligence to monetize the digital health innovation, or at least ensure optionality through the product development cycle.
Jim Williams
Advertisement
Jim Williams is an associate director in Life Sciences at Guidehouse.
Articles by Jim Williams
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Novo Nordisk Stock Reacts to Recent Board Changes
2
Bob Mauch: Strengthening the Chain
3
The Long-Term Outlook for MFN Pricing: Far-Reaching Issues and Considerations
4
What Impact will DTC Programs Have on Prescription Drug Prices?
5
